HTG Molecular Diagnostics (NASDAQ:HTGM) updated its first quarter 2021 earnings guidance on Tuesday. The company provided EPS guidance of – for the period. The company issued revenue guidance of $1.40 million-$1.40 million, compared to the consensus revenue estimate of $2.39 million.
Separately, Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a buy rating to a hold rating in a research report on Monday, February 1st.
HTGM traded down $0.07 on Tuesday, reaching $4.43. 115,655 shares of the company traded hands, compared to its average volume of 144,550. The stock’s 50 day moving average price is $5.14 and its 200-day moving average price is $4.64. HTG Molecular Diagnostics has a 52-week low of $3.78 and a 52-week high of $13.80. The company has a market cap of $27.53 million, a price-to-earnings ratio of -1.07 and a beta of 1.63. The company has a debt-to-equity ratio of 0.58, a current ratio of 5.74 and a quick ratio of 5.48.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Read More: Moving Average (MA)
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.